<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02447497</url>
  </required_header>
  <id_info>
    <org_study_id>EM-05-013509</org_study_id>
    <nct_id>NCT02447497</nct_id>
  </id_info>
  <brief_title>In Vivo Patient Preoperative Skin Prep Persistence</brief_title>
  <official_title>Assessment of Antimicrobial Persistence of 3M CHG/IPA Preoperative Skin Preparation Against Resident Flora on the Abdominal and Inguinal Regions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>3M</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>3M</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to demonstrate persistence of the CHG/IPA Prep on skin flora of&#xD;
      the abdominal and inguinal regions of human subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to demonstrate persistence of the CHG/IPA Prep versus a saline&#xD;
      placebo on skin flora of the abdominal and inguinal regions of human subjects as measured by&#xD;
      change in microbial flora relative to baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of Skin Flora Recovery Post-prep Application Relative to Baseline</measure>
    <time_frame>Baseline, 48 hours and 72 hours post-prep application</time_frame>
    <description>The primary measure of persistence is the suppression of regrowth recovery relative to baseline (log10 CFU/cm^2) of skin flora at two defined post-prep sampling times relative to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as Assessed by Skin Irritation Scores Coded by Study Staff</measure>
    <time_frame>48 hours and 72 hours post-product application</time_frame>
    <description>For the conditions of erythema, edema, rash, and dryness, a rating of 0 (no reaction), 1 (mild and/or transient, limited to sensitive area), 2 (moderate, persisting over much of the product-exposed area), or 3 (severe, extending over most or all of the product-exposed area) was recorded on the Skin Irritation Rating form of the eCRF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as Assessed by Adverse Events</measure>
    <time_frame>To 72 hours post treatment</time_frame>
    <description>Number of subjects with adverse events as self-reported or identified by study staff</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Bacterial Recovery of Skin Flora Post-Product Application</condition>
  <arm_group>
    <arm_group_label>3M CHG/IPA - Abdominal Region</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline - Abdominal Region</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Apply 0.9% sodium chloride with applicator for 30 seconds and allow to dry for 3 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3M CHG/IPA - Inguinal Region</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline - Inguinal Region</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Apply 0.9% sodium chloride with applicator for 30 seconds and allow to dry for 3 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3M CHG/IPA Surgical Skin Preparation - Abdominal Region</intervention_name>
    <description>Chlorhexidine gluconate 2% / Isopropyl alcohol 70%</description>
    <arm_group_label>3M CHG/IPA - Abdominal Region</arm_group_label>
    <other_name>SoluPrep</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline - Abdominal Region</intervention_name>
    <description>0.9% sodium chloride applied with foam applicator</description>
    <arm_group_label>Normal Saline - Abdominal Region</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3M CHG/IPA Surgical Skin Preparation - Inguinal Region</intervention_name>
    <description>Chlorhexidine gluconate 2% / Isopropyl alcohol 70%</description>
    <arm_group_label>3M CHG/IPA - Inguinal Region</arm_group_label>
    <other_name>SoluPrep</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline - Inguinal Region</intervention_name>
    <description>0.9% sodium chloride applied with foam applicator</description>
    <arm_group_label>Normal Saline - Inguinal Region</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects of any race&#xD;
&#xD;
          -  Subjects in good general health&#xD;
&#xD;
          -  Minimum skin flora baseline requirements on abdomen and groin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any tattoos, scars, breaks in the skin, or any form of dermatitis, or other skin&#xD;
             disorders (including acne) on the applicable test areas&#xD;
&#xD;
          -  Topical antimicrobial exposure within 14 days prior to screening and treatment days&#xD;
&#xD;
          -  Use of systemic or topical antibiotics, steroid medications, or any other products&#xD;
             known to affect the normal microbial flora of the skin within 14 days prior to&#xD;
             screening and treatment days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammad H Bashir, MD, CCRP</last_name>
    <role>Principal Investigator</role>
    <affiliation>MicroBioTest Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MicroBioTest</name>
      <address>
        <city>Sterling</city>
        <state>Virginia</state>
        <zip>20164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 8, 2015</study_first_submitted>
  <study_first_submitted_qc>May 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <results_first_submitted>October 5, 2020</results_first_submitted>
  <results_first_submitted_qc>October 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 23, 2020</results_first_posted>
  <disposition_first_submitted>February 8, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>February 8, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 9, 2017</disposition_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This is a randomized, paired-comparisons design where each subject will receive two of the planned treatments, one on the left side of body and one on the right.&#xD;
Each subject provided two abdomen test sites, left or right, and/or two inguinal test sites, left or right. A total of 25 subjects were randomized to the abdomen region and 23 subjects were randomized to the inguinal region resulting in 27 subjects providing 96 application test sites on two anatomical regions.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>3M CHG/IPA - Abdominal Region</title>
          <description>Experimental CHG/IPA Prep was randomly assigned to the left or right side of the abdominal test site</description>
        </group>
        <group group_id="P2">
          <title>Normal Saline - Abdominal Region</title>
          <description>Saline control was randomly assigned to the left or right side of the abdominal test site</description>
        </group>
        <group group_id="P3">
          <title>3M CHG/IPA Prep - Inguinal Region</title>
          <description>Experimental CHG/IPA Prep was randomly assigned to the left or right side of the inguinal test site</description>
        </group>
        <group group_id="P4">
          <title>Normal Saline - Inguinal Region</title>
          <description>Saline control was randomly assigned to the left or right side of the inguinal test site</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not meet treatment day baseline.</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dressing was compromised</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects with average treatment day baseline counts of &gt; or equal to 3.00 log10 CFU/cm2 bilaterally on abdominal (abd) region and/or &gt; or equal to 5.00 log10 CFU/cm2 bilaterally on inguinal (ing) region were included in the analysis.&#xD;
27 unique subjects provided 50 abd baseline test sites (25 rt &amp; 25 lt) &amp; 46 ing test sites (23 right &amp; 23 left).&#xD;
21 unique subjects provided abd &amp; ing test sites; 4 unique subjects provided abd only test sites; 2 unique subjects provided ing only test sites.</population>
      <group_list>
        <group group_id="B1">
          <title>3M CHG/IPA - Abdominal Region - Left or Right</title>
          <description>Experimental CHG/IPA Prep was randomly assigned to the left or right side of the abdominal test site</description>
        </group>
        <group group_id="B2">
          <title>Normal Saline - Abdominal Region - Left or Right</title>
          <description>Saline control was randomly assigned to the left or right side of the abdominal test site</description>
        </group>
        <group group_id="B3">
          <title>3M CHG/IPA Prep - Inguinal Region - Left or Right</title>
          <description>Experimental CHG/IPA Prep was randomly assigned to the left or right side of the inguinal test site</description>
        </group>
        <group group_id="B4">
          <title>Normal Saline - Inguinal Region - Left or Right</title>
          <description>Saline control was randomly assigned to the left or right side of the inguinal test site</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="23"/>
            <count group_id="B5" value="27"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Test sites on skin</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="23"/>
            <count group_id="B5" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <population>Twenty-seven (27) unique subjects provided 50 abdominal baseline test sites (25 right and 25 left) and 46 inguinal test sites (23 right and 23 left).</population>
          <units>Test sites on skin</units>
          <param>Number</param>
          <units_analyzed>Test sites on skin</units_analyzed>
          <class_list>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=66 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <population>Twenty-seven (27) unique subjects provided 50 abdominal baseline test sites (25 right and 25 left) and 46 inguinal test sites (23 right and 23 left).</population>
          <units>Test sites on skin</units>
          <param>Number</param>
          <units_analyzed>Test sites on skin</units_analyzed>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Twenty-seven (27) unique subjects provided 50 abdominal baseline test sites (25 right and 25 left) and 46 inguinal test sites (23 right and 23 left).</population>
          <units>Test sites on skin</units>
          <param>Number</param>
          <units_analyzed>Test sites on skin</units_analyzed>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>Twenty-seven (27) unique subjects provided 50 abdominal baseline test sites (25 right and 25 left) and 46 inguinal test sites (23 right and 23 left).</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Skin Flora Recovery Post-prep Application Relative to Baseline</title>
        <description>The primary measure of persistence is the suppression of regrowth recovery relative to baseline (log10 CFU/cm^2) of skin flora at two defined post-prep sampling times relative to baseline.</description>
        <time_frame>Baseline, 48 hours and 72 hours post-prep application</time_frame>
        <population>Number analyzed includes subjects who met baseline requirements</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline - Abdominal Region</title>
            <description>Saline control was randomly assigned to the left or right side of the abdominal test site</description>
          </group>
          <group group_id="O2">
            <title>3M CHG/IPA Prep - Abdominal Region</title>
            <description>Experimental CHG/IPA Prep was randomly assigned to the left or right side of the abdominal test site</description>
          </group>
          <group group_id="O3">
            <title>Normal Saline - Inguinal Region</title>
            <description>Saline control was randomly assigned to the left or right side of the inguinal test site</description>
          </group>
          <group group_id="O4">
            <title>3M CHG/IPA Prep - Inguinal Region</title>
            <description>Experimental CHG/IPA Prep was randomly assigned to the left or right side of the inguinal test site</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Skin Flora Recovery Post-prep Application Relative to Baseline</title>
          <description>The primary measure of persistence is the suppression of regrowth recovery relative to baseline (log10 CFU/cm^2) of skin flora at two defined post-prep sampling times relative to baseline.</description>
          <population>Number analyzed includes subjects who met baseline requirements</population>
          <units>Log10 CFU/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>48-hour timepoint</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.78"/>
                    <measurement group_id="O2" value="2.81" spread="0.97"/>
                    <measurement group_id="O3" value="0.59" spread="0.79"/>
                    <measurement group_id="O4" value="2.96" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72-hour timepoint</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="1.07"/>
                    <measurement group_id="O2" value="2.44" spread="1.34"/>
                    <measurement group_id="O3" value="0.51" spread="0.73"/>
                    <measurement group_id="O4" value="2.91" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hours post treatment time point. The primary analysis used a modified intent to treat population. Subjects were excluded who did not meet the treatment day baseline requirement of greater than or equal to 3.0 log10 CFU/cm^2 on the abdomen. The null hypothesis is that there is no difference in log10 CFU/cm^2 recovery between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Paired t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>4.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>48 hours post treatment. The primary analysis used a modified intent to treat population. Subjects were excluded who did not meet the treatment day baseline requirement of greater than or equal to 3.0 log10 CFU/cm^2 on the groin. The null hypothesis is that there is no difference in log10 CFU/cm^2 recovery between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Paired t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>5.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>72 hours post treatment. The primary analysis used a modified intent to treat population. Subjects were excluded who did not meet the treatment day baseline requirement of greater than or equal to 3.0 log10 CFUcm2 on the groin. The null hypothesis is that there is no difference in log10 CFU/cm^2 recovery between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Paired t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>3.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>72 hours post treatment. The primary analysis used a modified intent to treat population. Subjects were excluded who did not meet the treatment day baseline requirement of greater than or equal to 3.0 log10 CFUcm2 on the groin. The null hypothesis is that there is no difference in log10 CFU/cm^2 recovery between arms.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Paired t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>5.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety as Assessed by Skin Irritation Scores Coded by Study Staff</title>
        <description>For the conditions of erythema, edema, rash, and dryness, a rating of 0 (no reaction), 1 (mild and/or transient, limited to sensitive area), 2 (moderate, persisting over much of the product-exposed area), or 3 (severe, extending over most or all of the product-exposed area) was recorded on the Skin Irritation Rating form of the eCRF.</description>
        <time_frame>48 hours and 72 hours post-product application</time_frame>
        <population>Data from the 48-hour and 72-hour timepoints were combined for each skin condition category of erythema, edema, rash and erythema since all ratings for all subjects at all timepoints were scored as zero (no reaction) for all subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>3M CHG/IPA - Abdominal Area</title>
            <description>Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70%&#xD;
3M CHG/IPA Surgical Skin Preparation: Chlorhexidine gluconate 2% / Isopropyl alcohol 70%</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline - Abdominal Area</title>
            <description>0.9% sodium chloride with applicator&#xD;
Normal Saline: 0.9% sodium chloride applied with foam applicator</description>
          </group>
          <group group_id="O3">
            <title>3M CHG/IPA - Inguinal Area</title>
            <description>Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70%&#xD;
3M CHG/IPA Surgical Skin Preparation: Chlorhexidine gluconate 2% / Isopropyl alcohol 70%</description>
          </group>
          <group group_id="O4">
            <title>Normal Saline - Inguinal Area</title>
            <description>0.9% sodium chloride with applicator&#xD;
Normal Saline: 0.9% sodium chloride applied with foam applicator</description>
          </group>
        </group_list>
        <measure>
          <title>Safety as Assessed by Skin Irritation Scores Coded by Study Staff</title>
          <description>For the conditions of erythema, edema, rash, and dryness, a rating of 0 (no reaction), 1 (mild and/or transient, limited to sensitive area), 2 (moderate, persisting over much of the product-exposed area), or 3 (severe, extending over most or all of the product-exposed area) was recorded on the Skin Irritation Rating form of the eCRF.</description>
          <population>Data from the 48-hour and 72-hour timepoints were combined for each skin condition category of erythema, edema, rash and erythema since all ratings for all subjects at all timepoints were scored as zero (no reaction) for all subjects.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema: 48-hour timepoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: 72-hour timepoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema: 48-hour timepoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema: 72-hour timepoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash: 48-hour timepoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash: 72-hour timepoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dryness: 48-hour timepoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dryness: 72-hour timepoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety as Assessed by Adverse Events</title>
        <description>Number of subjects with adverse events as self-reported or identified by study staff</description>
        <time_frame>To 72 hours post treatment</time_frame>
        <population>Adverse event reports through the treatment period, that is both 48 and 72 hours post dose.</population>
        <group_list>
          <group group_id="O1">
            <title>3M CHG/IPA - Abdomen</title>
            <description>Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70%&#xD;
3M CHG/IPA Surgical Skin Preparation: Chlorhexidine gluconate 2% / Isopropyl alcohol 70%&#xD;
Applied to the abdominal area</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline - Abdomen</title>
            <description>0.9% sodium chloride with applicator&#xD;
Normal Saline: 0.9% sodium chloride applied with foam applicator&#xD;
Applied to the abdominal area</description>
          </group>
          <group group_id="O3">
            <title>3M CHG/IPA - Inguinal</title>
            <description>Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70%&#xD;
3M CHG/IPA Surgical Skin Preparation: Chlorhexidine gluconate 2% / Isopropyl alcohol 70%&#xD;
Applied to the inguinal area</description>
          </group>
          <group group_id="O4">
            <title>Normal Saline - Inguinal</title>
            <description>0.9% sodium chloride with applicator&#xD;
Normal Saline: 0.9% sodium chloride applied with foam applicator&#xD;
Applied to the inguinal area</description>
          </group>
        </group_list>
        <measure>
          <title>Safety as Assessed by Adverse Events</title>
          <description>Number of subjects with adverse events as self-reported or identified by study staff</description>
          <population>Adverse event reports through the treatment period, that is both 48 and 72 hours post dose.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the treatment phase of the study. The product remained on the skin for approximately 72 hours post.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>3M CHG/IPA - Abdomen</title>
          <description>Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70%&#xD;
3M CHG/IPA Surgical Skin Preparation: Chlorhexidine gluconate 2% / Isopropyl alcohol 70%&#xD;
Applied to the abdominal area</description>
        </group>
        <group group_id="E2">
          <title>Normal Saline - Abdomen</title>
          <description>0.9% sodium chloride with applicator&#xD;
Normal Saline: 0.9% sodium chloride applied with foam applicator&#xD;
Applied to the abdominal area</description>
        </group>
        <group group_id="E3">
          <title>3M CHG/IPA - Inguinal</title>
          <description>Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70%&#xD;
3M CHG/IPA Surgical Skin Preparation: Chlorhexidine gluconate 2% / Isopropyl alcohol 70%&#xD;
Applied to the inguinal area</description>
        </group>
        <group group_id="E4">
          <title>Normal Saline - Inguinal</title>
          <description>0.9% sodium chloride with applicator&#xD;
Normal Saline: 0.9% sodium chloride applied with foam applicator&#xD;
Applied to the inguinal area</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nancy Klinger</name_or_title>
      <organization>3M</organization>
      <phone>651 491 9433</phone>
      <email>nmklinger@mmm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

